OncoDaily’s Post

Our review article on ARPI + PARPi in Prostate Cancer - Arun Azad (Peter MacCallum Cancer Centre) #Oncology #Cancer #Research #ProstateCancer #ReviewArticle #OncoDaily

Desmoplastic small round cell tumor (DSRCT) is an aggressive pediatric #cancer with extremely poor prognosis due to its resistance to many treatment types. Using transcriptomic analysis of a novel cancer model, the lab of Tulane's Dr. Sean Lee has identified B-lymphocyte kinase as a potential drug target to reduce DSRCT chemotherapy resistance. #TulaneResearch #Oncology Read the paper in the comments! Image: Three different DSRCT cell lines (rows) at baseline or treated with different levels of two compounds known to inhibit B-lymphocyte kinase. Treatment decreased cancer cell viability, as quantified in bar graphs.

This is a great summary article and a quick read! The evolution of identifying targetable mutations in tumors, especially those overexpressing genes like HER2 (human epidermal growth factor receptor 2) in breast cancer, has been remarkable. It's incredible how far we've come in such a short period. HER2 (ERBB2) overexpression occurs in ~15-30% of breast cancers, ~10-30% of gastroesophageal cancers, and 3–80% of colorectal cancers (with 1-60% amplification). It’s also present in bladder, pancreatic, ovarian, endometrial, lung, kidney, and some head and neck tumors. Antibody-drug conjugates (ADCs), like trastuzumab deruxtecan, offer a promising approach by linking chemotherapeutic "payload" agents to antibodies designed to target and bind to cell surface proteins such as HER2. The potential for infinite combinatorial approaches makes the future look bright, with the hope of transforming a deadly cancer diagnosis into a manageable chronic illness. The combination of ADCs, PARP inhibitors (PARPi), and immunotherapies, along with the future fine-tuning of combination therapies, aims to force tumors to increase their immunogenicity and disable their ability to divide and reproduce. By trapping their DNA damage repair systems like HR and causing single-stranded breaks (SSBs) to degrade into double-stranded breaks (DSBs), we hope to induce cell death in these tumor cells. This is an exciting horizon for anyone in this field! I wish my mother, grandparents, and aunts and uncles could be here to see how far we've come and witness where we are headed! #ADC #PARPi #Immunooncology #PrecisonOncology

🔬 Insights from ASCO 2024! Dr Antonio Marra from the European Institute of Oncology discusses cyclin-E1 amplification in advanced breast cancer. This subset of patients shows poor outcomes with standard therapies but promising responses with PKMYT1 and CDK-2 inhibitors in preclinical models. Learn about the potential for new targeted treatments. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #CyclinE1

Eric S. Winer, MD, Clinical Director of Adult Leukemia at Dana-Farber Cancer Institute, and an Assistant Professor of Medicine at Harvard Medical School, highlights the progress of TakeAim Leukemia study. He notes, "It's been terrific to see the results of emavusertib (CA-4948); what’s nice about emavusertib is it seems to work well in patients with FLT3 mutations, but also in those who have previously received FLT3 inhibitors." #CRIS #oncology #hematology #drugdevelopment #emavusertib Emavusertib Progresses to Phase 2 Study in AML and MDS (onclive.com)

Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives 🔬 #ClinicalOncology #Oncology #Cancer

Challenges in utilizing mutation testing in AML - Video Journal of Hematology & Hematological Oncology (VJHemOnc) Sanam Loghavi MD Anderson Cancer Center European Hematology Association (EHA) #Cancer #MDAndersonCancerCenter #OncoDaily #Oncology #Hematology #HematologicalOncology

Target Therapy in Thyroid Cancer: Current Challenges in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects 📄Read here: https://lnkd.in/gDybBfZT Key points: - Advances in tyrosine kinase inhibitors (TKIs) for thyroid cancer. - Challenges and strategies for managing side effects. #ThyroidCancer #MedicalResearch #Endocrinology #Oncology #TKI #HealthcareInnovation

Talazoparib in Combination With Enzalutamide for Prostate Cancer - FDA Oncology #Cancer #Enzalutamide #FDAApproval #Oncology #OncoDaily #Oncology #Talazoparib

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial Ben Solomon Fabrice Barlesi Alice Shaw Walter Bordogna Roche American Society of Clinical Oncology (ASCO) https://lnkd.in/dQApcgWi #Cancer #Alectinib #ALINATrial #NSCLC #ClinicalTrial #DrugApproval #FDAApproved #JournalOfClinicalOncology #LungCancer #OncoDaily #Oncology